AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25315667 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet supplemented with nuts (Med‐nuts)
Number of subjects: 200
Study 25315667 — intervention group
Group type: COMPARATOR
Intervention: Low-fat control diet
Number of subjects: 200
Study 23579344 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-combination brinzolamide, 1%, and brimonidine, 0.2%
Number of subjects: 660
Study 23579344 — intervention group
Group type: COMPARATOR
Intervention: Brinzolamide, 1%
Number of subjects: 660
Study 23579344 — intervention group
Group type: COMPARATOR
Intervention: Brimonidine, 0.2%
Number of subjects: 660
Study 20522466 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-mentoring by a lay-worker fortnightly during pregnancy and monthly for the following year, tailored to participants' wishes (home visits/telephone contacts), additional to usual care.
Number of subjects: 343
Study 20522466 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer-mentoring by a lay-worker
Number of subjects: 343
Study 19365055 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune globulin IV, 10% caprylate/chromatography purified (IGIV-C)
Number of subjects: 117
Study 19365055 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 117
Study 17533747 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy plus CMNa (group-A)
Number of subjects: 211
Study 17533747 — intervention group
Group type: COMPARATOR
Intervention: Radiotherapy alone (group-B)
Number of subjects: 211
Study 15291711 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Education Program (HEP)
Number of subjects: 0
Study 15291711 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 0
Study 11728623 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomization procedures implemented in clinical trials
Number of subjects: 0
Study 9160916 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (local treatment for 4 weeks)
Number of subjects: 0
Study 9160916 — intervention group
Group type: COMPARATOR
Intervention: Control (normal subjects)
Number of subjects: 0
Study 8105773 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine administered before and after the procedure
Number of subjects: 248
Study 8105773 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine administered before the procedure
Number of subjects: 248
Study 8105773 — intervention group
Group type: EXPERIMENTAL
Intervention: Brimonidine administered after the procedure
Number of subjects: 248
Study 8105773 — intervention group
Group type: COMPARATOR
Intervention: Vehicle administered before and after the procedure
Number of subjects: 248
Study 3114306 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin (mevinolin)
Number of subjects: 16
Study 3114306 — intervention group
Group type: COMPARATOR
Intervention: Neomycin
Number of subjects: 16
Study 29314350 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based cognitive rehabilitation intervention (4-week online program)
Number of subjects: 51
Study 29314350 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-cancer treatment group (4-week online program)
Number of subjects: 51
Study 26774112 — intervention group
Group type: EXPERIMENTAL
Intervention: Foley catheter with 80 mL
Number of subjects: 154
Study 26774112 — intervention group
Group type: COMPARATOR
Intervention: Foley catheter with 30 mL
Number of subjects: 154
Study 26774112 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (80 mL and 30 mL)
Number of subjects: 154
Study 24888209 — intervention group
Group type: EXPERIMENTAL
Intervention: Yoga intervention
Number of subjects: 38
Study 24888209 — intervention group
Group type: COMPARATOR
Intervention: Assessment control
Number of subjects: 38
Study 21846427 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping with depression course
Number of subjects: 101
Study 20160156 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial-block crossover design for dutasteride
Number of subjects: 0
Study 20160156 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulations of the partial-block crossover design
Number of subjects: 0
Study 20160156 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous single-dose dutasteride studies
Number of subjects: 0
Study 18571226 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives of $50 plus up to $25 more per week based on aerobic minutes (10+ minutes of continuous walking or jogging)
Number of subjects: 51
Study 18571226 — intervention group
Group type: COMPARATOR
Intervention: Fixed payment of $75
Number of subjects: 51
Study 16669843 — intervention group
Group type: EXPERIMENTAL
Intervention: β‐adrenoceptor blockers
Number of subjects: 0
Study 16669843 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic agents
Number of subjects: 0
Study 14636909 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol 100 mg twice daily for 6 weeks
Number of subjects: 40
Study 14636909 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 40
Study 14636909 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 10954953 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan nasal spray (20 mg)
Number of subjects: 368
Study 10954953 — intervention group
Group type: COMPARATOR
Intervention: Dihydroergotamine nasal spray (1 mg plus optional 1 mg)
Number of subjects: 368
Study 8623945 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: 20 mL of propofol alone in a commercial preparation (Diprivan(R) with 10 mL of saline)
Number of subjects: 36
Study 8623945 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: 20 mL of propofol and 10 mL of LCT fat emulsion
Number of subjects: 36
Study 8623945 — intervention group
Group type: COMPARATOR
Intervention: Group B: 20 mL of propofol with 5 mL of long‐chain triglyceride (LCT) fat emulsion and 5 mL of saline
Number of subjects: 36
Study 1422747 — intervention group
Group type: EXPERIMENTAL
Intervention: Stripping of the long saphenous vein (LSV) to the upper calf (n = 49)
Number of subjects: 69
Study 1422747 — intervention group
Group type: COMPARATOR
Intervention: SFJ ligation alone (n = 56)
Number of subjects: 69
Study 1422747 — intervention group
Group type: EXPERIMENTAL
Intervention: Stripping of the long saphenous vein (LSV) to the upper calf
Number of subjects: 69
Study 1422747 — intervention group
Group type: COMPARATOR
Intervention: SFJ ligation alone
Number of subjects: 69
Study 6378105 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 28
Study 6378105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 31064379 — intervention group
Group type: EXPERIMENTAL
Intervention: PThC (Critical Inspiratory Pressure)
Number of subjects: 30
Study 31064379 — intervention group
Group type: EXPERIMENTAL
Intervention: 60% of MIP (Maximal Inspiratory Pressure)
Number of subjects: 30
Study 31064379 — intervention group
Group type: COMPARATOR
Intervention: Sham (SG)
Number of subjects: 30
Study 29373753 — intervention group
Group type: EXPERIMENTAL
Intervention: Dicer partner protein Loquacious‐PB (Loqs‐PB)
Number of subjects: 0
Study 29373753 — intervention group
Group type: EXPERIMENTAL
Intervention: Base-mismatch in the pre-miRNA stem
Number of subjects: 0
Study 29373753 — intervention group
Group type: EXPERIMENTAL
Intervention: Dram-seq method
Number of subjects: 0
Study 27534645 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B‐12 status (total vitamin B‐12, holotranscobalamin, cB‐12)
Number of subjects: 201
Study 27534645 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B‐12 status
Number of subjects: 201
Study 24629718 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness eating and yoga exercise
Number of subjects: 0
Study 23106878 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (TU) capsules, 120 - 160 mg daily for 6 months
Number of subjects: 160
Study 23106878 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (TU) capsules
Number of subjects: 160
Study 23106878 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E/C capsules (control)
Number of subjects: 160
Study 19811509 — intervention group
Group type: EXPERIMENTAL
Intervention: 3T MRI without o-CRH stimulation
Number of subjects: 21
Study 19811509 — intervention group
Group type: EXPERIMENTAL
Intervention: 3T MRI with o-CRH stimulation
Number of subjects: 21
Study 19811509 — intervention group
Group type: COMPARATOR
Intervention: 3T MRI
Number of subjects: 21
Study 19811509 — intervention group
Group type: COMPARATOR
Intervention: 1.5T MRI
Number of subjects: 21
Study 18626271 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 18626271 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose (1.0 mg/kg) MDMA
Number of subjects: 8
Study 18626271 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose (1.6 mg/kg) MDMA
Number of subjects: 8
Study 16143742 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer counseling group (PC)
Number of subjects: 162
Study 16143742 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 162
Study 11791092 — intervention group
Group type: EXPERIMENTAL
Intervention: Trovafloxacin
Number of subjects: 311
Study 11791092 — intervention group
Group type: COMPARATOR
Intervention: Ceftriaxone with or without vancomycin
Number of subjects: 311
Study 10220130 — intervention group
Group type: EXPERIMENTAL
Intervention: New antipsychotics
Number of subjects: 0
Study 10220130 — intervention group
Group type: COMPARATOR
Intervention: Reference antipsychotic
Number of subjects: 0
Study 7794082 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical resection
Number of subjects: 50
Study 7794082 — intervention group
Group type: COMPARATOR
Intervention: Radiation therapy
Number of subjects: 50
Study 7794082 — intervention group
Group type: COMPARATOR
Intervention: Operative palliation
Number of subjects: 50
Study 2064541 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexually explicit videotape (experimental group)
Number of subjects: 0
Study 2064541 — intervention group
Group type: COMPARATOR
Intervention: Nonerotic videotape (control group)
Number of subjects: 0
Study 2064541 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexually explicit videotape (both groups after 90 minutes)
Number of subjects: 0
Study 2064541 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (across the session)
Number of subjects: 0
Study 2064541 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (correlation analysis)
Number of subjects: 0
Study 7140708 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 ppm SO2
Number of subjects: 24
Study 7140708 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.50 ppm SO2
Number of subjects: 24
Study 7140708 — intervention group
Group type: COMPARATOR
Intervention: 0 ppm SO2 (Control)
Number of subjects: 24
Study 7140708 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 24
Study 31554388 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day high dose PPI-bismuth-containing quadruple therapy with probiotics (37.5 mg Lactobacillus reuteri, Biogaia® in tablet twice daily)
Number of subjects: 100
Study 31554388 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-day high dose PPI-bismuth-containing quadruple therapy with probiotics
Number of subjects: 100
Study 31554388 — intervention group
Group type: EXPERIMENTAL
Intervention: 14-day high dose PPI-bismuth-containing quadruple therapy with probiotics
Number of subjects: 100
Study 31554388 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics group
Number of subjects: 100
Study 29143416 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren
Number of subjects: 1306
Study 27858873 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy + Dexrazoxane (Chemo + DRZ)
Number of subjects: 110
Study 27858873 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (Chemo)
Number of subjects: 110
Study 25213806 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive consultations with a general practitioner
Number of subjects: 364
Study 25213806 — intervention group
Group type: EXPERIMENTAL
Intervention: Responders after telephone reminding
Number of subjects: 364
Study 25213806 — intervention group
Group type: COMPARATOR
Intervention: Primary responders
Number of subjects: 364
Study 23140338 — intervention group
Group type: EXPERIMENTAL
Intervention: Short theory of mind intervention
Number of subjects: 100
Study 23140338 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 100
Study 20298496 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week (eow)
Number of subjects: 0
Study 20298496 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg weekly
Number of subjects: 0
Study 20298496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 20298496 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (adalimumab eow, adalimumab weekly, placebo)
Number of subjects: 0
Study 20298496 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 0
Study 18205098 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren (150 mg titrated to 300 mg after four weeks)
Number of subjects: 837
Study 18205098 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril (5 mg titrated to 10 mg)
Number of subjects: 837
Study 18205098 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren and Ramipril combination
Number of subjects: 837
Study 15656327 — intervention group
Group type: EXPERIMENTAL
Intervention: Epoetin alfa
Number of subjects: 114
Study 15656327 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 114
Study 11802936 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapleural urokinase
Number of subjects: 81
Study 11802936 — intervention group
Group type: COMPARATOR
Intervention: Conventional group
Number of subjects: 81
Study 11802936 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 81
Study 9543117 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium supplement (714 mg Ca/day)
Number of subjects: 60
Study 9543117 — intervention group
Group type: COMPARATOR
Intervention: Placebo (total Ca intake, 288 +/- 128 mg/day)
Number of subjects: 60
Study 7850816 — intervention group
Group type: EXPERIMENTAL
Intervention: Renal transplantation (RT) with blood pressure decrease (group I)
Number of subjects: 30
Study 7850816 — intervention group
Group type: COMPARATOR
Intervention: Renal transplantation (RT) with blood pressure increase (group II)
Number of subjects: 30
Study 2844981 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate daily ganciclovir maintenance therapy
Number of subjects: 11
Study 2844981 — intervention group
Group type: COMPARATOR
Intervention: Deferred maintenance therapy
Number of subjects: 11
Study 2844981 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferred maintenance therapy after crossover
Number of subjects: 11
Study 2844981 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintenance therapy
Number of subjects: 11
Study 2844981 — intervention group
Group type: COMPARATOR
Intervention: Off maintenance therapy
Number of subjects: 11
Study 31590179 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone (NTX; 50 mg/day) + placebo memantine
Number of subjects: 56
Study 31590179 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (NTX; 50 mg/day) + memantine (MEM; 20 mg/day)
Number of subjects: 56
Study 31590179 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone (NTX; 50 mg/day) alone
Number of subjects: 56
Study 30954042 — intervention group
Group type: EXPERIMENTAL
Intervention: MOB-ML method
Number of subjects: 7211
Study 28700036 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard cognitive training program
Number of subjects: 6
Study 28700036 — intervention group
Group type: COMPARATOR
Intervention: Controlled placebo condition
Number of subjects: 6
Study 25440636 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory rate of 15 cycles/min with low-tidal-volume (5 mL/kg) and two-lung ventilation
Number of subjects: 48
Study 25440636 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory rate of 18 cycles/min with low-tidal-volume (5 mL/kg) and two-lung ventilation
Number of subjects: 48
Study 25440636 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory rate of 22 cycles/min with low-tidal-volume (5 mL/kg) and two-lung ventilation
Number of subjects: 48
Study 24377221 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent wave (IW) electroacupuncture combined with rehabilitation therapy
Number of subjects: 75
Study 24377221 — intervention group
Group type: EXPERIMENTAL
Intervention: Disperse-dense wave (DW) electroacupuncture combined with rehabilitation therapy
Number of subjects: 75
Study 24377221 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous wave (CW) electroacupuncture combined with rehabilitation therapy
Number of subjects: 75
Study 21278214 — intervention group
Group type: EXPERIMENTAL
Intervention: MRKAd5 HIV-1 gag/pol/nef vaccine
Number of subjects: 0
Study 21278214 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-B alleles associated with HIV-1 control
Number of subjects: 0
Study 21278214 — intervention group
Group type: EXPERIMENTAL
Intervention: Host immunogenetic background
Number of subjects: 0
Study 19917887 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantable cardioverter-defibrillator (ICD) therapy
Number of subjects: 2521
Study 19917887 — intervention group
Group type: COMPARATOR
Intervention: Amiodarone
Number of subjects: 2521
Study 19917887 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2521
Study 15542278 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibition
Number of subjects: 234
Study 15542278 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin II antagonism
Number of subjects: 234
Study 10077713 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 40
Study 10077713 — intervention group
Group type: COMPARATOR
Intervention: Needling at non-acupuncture points (Control)
Number of subjects: 40
Study 7672690 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle training with visual biofeedback (EMG record visible to the patient)
Number of subjects: 0
Study 7672690 — intervention group
Group type: COMPARATOR
Intervention: Muscle training without visual biofeedback
Number of subjects: 0
Study 2258782 — intervention group
Group type: EXPERIMENTAL
Intervention: Betaxolol
Number of subjects: 17
Study 2258782 — intervention group
Group type: COMPARATOR
Intervention: Verapamil
Number of subjects: 17
Study 7422170 — intervention group
Group type: EXPERIMENTAL
Intervention: ethinyl estradiol, 50 microgram per day
Number of subjects: 49
Study 7422170 — intervention group
Group type: EXPERIMENTAL
Intervention: levonorgestrel, 250 microgram per day
Number of subjects: 49
Study 7422170 — intervention group
Group type: EXPERIMENTAL
Intervention: combination of ethinyl estradiol and levonorgestrel (Nordiol)
Number of subjects: 49
Study 7422170 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 49
Study 30565715 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% CHx‐based product applied with scrub technique
Number of subjects: 0
Study 30565715 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% CHx‐based product applied with rub technique
Number of subjects: 0
Study 30565715 — intervention group
Group type: EXPERIMENTAL
Intervention: CHx/alcohol‐combination (1% CHx and 61% ethanol) applied with rub technique
Number of subjects: 0
Study 30565715 — intervention group
Group type: EXPERIMENTAL
Intervention: Sole ABR (80% ethanol) applied with rub technique
Number of subjects: 0
Study 30565715 — intervention group
Group type: COMPARATOR
Intervention: CHx‐scrub technique
Number of subjects: 0
Study 28548210 — intervention group
Group type: EXPERIMENTAL
Intervention: Xenogeneic collagen matrix (XCM)
Number of subjects: 60
Study 28548210 — intervention group
Group type: COMPARATOR
Intervention: Connective tissue graft (CTG)
Number of subjects: 60
Study 26156568 — intervention group
Group type: EXPERIMENTAL
Intervention: YouTube
Number of subjects: 0
Study 26156568 — intervention group
Group type: COMPARATOR
Intervention: Twitter
Number of subjects: 0
Study 26156568 — intervention group
Group type: COMPARATOR
Intervention: Facebook
Number of subjects: 0
Study 26156568 — intervention group
Group type: COMPARATOR
Intervention: Blogs
Number of subjects: 0
Study 24598495 — intervention group
Group type: EXPERIMENTAL
Intervention: Semilunar coronally positioned flap technique
Number of subjects: 20
Study 24598495 — intervention group
Group type: COMPARATOR
Intervention: Coronally advanced flap technique
Number of subjects: 20
Study 21755358 — intervention group
Group type: EXPERIMENTAL
Intervention: Lengthening contractions (LC)
Number of subjects: 9
Study 21755358 — intervention group
Group type: COMPARATOR
Intervention: Shortening contractions (SC)
Number of subjects: 9
Study 19615653 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple loop suture
Number of subjects: 15
Study 19615653 — intervention group
Group type: COMPARATOR
Intervention: Anchor suture
Number of subjects: 15
Study 19615653 — intervention group
Group type: COMPARATOR
Intervention: Comparison between groups
Number of subjects: 15
Study 17615800 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous dalteparin (5000 IU) once daily
Number of subjects: 3706
Study 17615800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3706
Study 15543329 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin K(1)-containing multivitamin (25 mcg daily for 4 weeks)
Number of subjects: 16
Study 15543329 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K(1)-free multivitamin (4 weeks)
Number of subjects: 16
Study 11994558 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination drug therapy with glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytics
Number of subjects: 0
Study 9685777 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics during intracranial pressure monitoring
Number of subjects: 30
Study 9685777 — intervention group
Group type: COMPARATOR
Intervention: No prophylactic antibiotics and no intracranial pressure monitoring
Number of subjects: 30
Study 7925510 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 6.25 mg, titrated to 25 mg t.i.d.
Number of subjects: 298
Study 7925510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 298
Study 2810673 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 22
Study 2810673 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 22